Clinical trial · Observational
The Impact of the COVID-19 Pandemic on Testicular Cancer
The Impact of the COVID-19 Pandemic on Oncologic Outcomes of Testicular Cancer
NCT05083143CI-TRIAL-00058072completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COVID-19 | — | UNRESOLVED | — |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COVID-19 pandemic | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- COVID-19 Testicular Cancer
- description
- Patients diagnosed with testicular cancer in the COVID-19 period
- interventionNames
- Behavioral: COVID-19 pandemic
- label
- PreCOVID-19 Testicular Cancer
- description
- Patients diagnosed with testicular cancer before the COVID-19 period
- interventionNames
- Behavioral: COVID-19 pandemic
Primary outcomes (1)
- measure
- Rate of tumor stages
- timeFrame
- 2 month
- description
- Rate of tumor stages in patients who diagnosed with testicular cancer
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with testicular cancer in the urology clinic. Exclusion Criteria: * Previous history of genitourinary system tumor * Previous history of radiotherapy or chemotherapy
References
Publications (3)
- BACKGROUNDYue H, Bai X, Wang J, Yu Q, Liu W, Pu J, Wang X, Hu J, Xu D, Li X, Kang N, Li L, Lu W, Feng T, Ding L, Li X, Qi X; Gansu Provincial Medical Treatment Expert Group of COVID-19. Clinical characteristics of coronavirus disease 2019 in Gansu province, China. Ann Palliat Med. 2020 Jul;9(4):1404-1412. doi: 10.21037/apm-20-887. Epub 2020 Jul 13. PMID 32692208
- BACKGROUNDMoul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol. 1990 Mar;143(3):520-3. doi: 10.1016/s0022-5347(17)40007-3. PMID 2304163
- BACKGROUNDWallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3. PMID 32414626